tirzepatide vs semaglutide efficacy weight loss comparison (Zepbound; Eli Lilly and Co) demonstrated 47% greater relative compared to (Wegovy; Novo Nordisk) in the SURMOUNT-5 phase 3b open-label trial. Full results will be presented at a tirzepatide vs semaglutide weight loss

Discontinuation because of gastrointestinal adverse reactions occurred in 3.1% and 3.8% of treated patients versus 0.4% on placebo, so most people who experienced symptoms continued

Here are some patient profiles that might benefit from them: Individuals with Type 2 Diabetes: Particularly those who haven't achieved adequate blood sugar control with other medications or lifestyle changes

We believe that wellness is for everyone, and feeling well starts with a personalized approach

Additionally, those taking medications for heart disease, blood pressure, or neurological conditions should be especially cautious

Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide